Esperion Therapeutics Inc (ESPR)
2.35
-0.24
(-9.27%)
USD |
NASDAQ |
May 17, 16:00
2.38
+0.03
(+1.28%)
After-Hours: 20:00
Esperion Therapeutics Cash from Investing (Quarterly): -0.073M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -0.073M |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 17.50M |
March 31, 2023 | 25.00M |
December 31, 2022 | -11.79M |
September 30, 2022 | 33.00M |
June 30, 2022 | 5.00M |
March 31, 2022 | -18.10M |
December 31, 2021 | -50.48M |
September 30, 2021 | 0.00 |
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | -12.68M |
September 30, 2020 | 2.333M |
June 30, 2020 | 5.11M |
March 31, 2020 | 26.59M |
December 31, 2019 | -2.868M |
September 30, 2019 | -5.313M |
June 30, 2019 | 26.72M |
March 31, 2019 | 45.70M |
December 31, 2018 | 38.57M |
September 30, 2018 | 40.03M |
June 30, 2018 | 31.57M |
March 31, 2018 | 30.28M |
Date | Value |
---|---|
December 31, 2017 | 48.40M |
September 30, 2017 | -127.52M |
June 30, 2017 | 27.10M |
March 31, 2017 | 16.17M |
December 31, 2016 | 7.752M |
September 30, 2016 | 13.07M |
June 30, 2016 | 19.26M |
March 31, 2016 | -29.96M |
December 31, 2015 | 5.345M |
September 30, 2015 | -37.26M |
June 30, 2015 | -70.61M |
March 31, 2015 | -57.55M |
December 31, 2014 | -38.88M |
September 30, 2014 | 0.785M |
June 30, 2014 | 0.347M |
March 31, 2014 | 1.153M |
December 31, 2013 | -7.654M |
September 30, 2013 | -13.39M |
June 30, 2013 | 0.037M |
March 31, 2013 | 0.001M |
December 31, 2012 | 0.0016M |
September 30, 2012 | 0.0026M |
June 30, 2012 | 0.00 |
March 31, 2012 | -0.0062M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-50.48M
Minimum
Dec 2021
33.00M
Maximum
Sep 2022
1.997M
Average
--
Median
Mar 2021
Cash from Investing (Quarterly) Benchmarks
United Therapeutics Corp | 735.30M |
Dynavax Technologies Corp | 2.831M |
Heron Therapeutics Inc | 1.278M |
Aldeyra Therapeutics Inc | -30.38M |
Deciphera Pharmaceuticals Inc | 62.63M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 53.83M |
Cash from Financing (Quarterly) | 90.61M |
Free Cash Flow | -27.38M |
Free Cash Flow Per Share (Quarterly) | 0.2835 |
Free Cash Flow to Equity (Quarterly) | 53.32M |
Free Cash Flow Yield | -8.91% |